---
title: "Bioxytran delays annual report as auditor needs more time on 2024 audit"
url: "https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/"
publisher: "aibio.space (Biotech Investor Relations News)"
date: "2025-03-31"
section: "Distress"
tickers: "OTC:BIXT"
source: "https://www.sec.gov/Archives/edgar/data/1445815/000164117225001878/formnt10-k.htm"
summary: "The company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period."
---

By the aibio.space news desk.

Sources

- [Bioxytran, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1445815/000164117225001878/formnt10-k.htm)

[BIXT](https://aibio.space/companies/bioxytran/)

2025-03-31

# Bioxytran delays annual report as auditor needs more time on 2024 audit

Tickers [BIXT](https://aibio.space/companies/bioxytran/)

The company filed a late notice for its Form 10-K for the year ended December 31, 2024. It expects to file within the fifteen-day grace period.

## Key facts

- **Company**: Bioxytran, Inc. (OTC: BIXT)

- **News type**: Distress

- **Primary source**: [Bioxytran, Inc. NT 10-K (2025-03-31)](https://www.sec.gov/Archives/edgar/data/1445815/000164117225001878/formnt10-k.htm)

*Rows of law reports on a shelf. CC0, via rawpixel. The picture shows the field, not the companies named.*

Bioxytran, Inc. has told the Securities and Exchange Commission that its annual report for the year ended December 31, 2024 will be late.

The company filed a notification of late filing on Form 12b-25, dated March 31, 2025. A company files this form when it cannot complete a periodic report on time without unreasonable effort or expense. For an annual report, the form allows a grace period of fifteen calendar days.

Bioxytran said its independent registered public accounting firm is still completing the audit of its financial statements for the period ended December 31, 2024. The auditor needs additional time to finish that work.

The company said it expects to file its Form 10-K within the fifteen-day grace period provided by Rule 12b-25 of the Securities Exchange Act of 1934.

In the form, Bioxytran said it does not expect the annual report to show a significant change in results of operations from the prior fiscal year. It also said it has filed all other periodic reports required during the preceding 12 months.

Bioxytran is based in Needham, Massachusetts.

[Report an error](https://aibio.space/reputation/#correction)

## Companies in this story

BIXT

Bioxytran, Inc.

OTC · United States

Open the starter desk

## More in Distress

Distress

### [Mineralys takes ownership of lorundrostat patents but keeps Tanabe milestone debts](https://aibio.space/news/mineralys-takes-ownership-lorundrostat-patents-but-keeps-tanabe/)

Oct 29, 2026

Distress

### [Bristol Myers Squibb drops Prothena's PRX019, ending up to $617.5 million in milestones](https://aibio.space/news/bristol-myers-squibb-drops-prothenas-prx019-ending-up-617-5-million/)

Oct 29, 2026

Distress

### [LENZ Therapeutics reorganizes to cut 2027 operating expenses by more than 50%](https://aibio.space/news/lenz-therapeutics-reorganizes-cut-2027-operating-expenses-more-50/)

Oct 28, 2026

---
Source page: https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Bioxytran delays annual report as auditor needs more time on 2024 audit", 2025-03-31, https://aibio.space/news/bioxytran-delays-annual-report-auditor-needs-more-time-2024-audit/